Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker
Open Access
- 26 March 2010
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 1-9
Abstract
Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.Keywords
This publication has 28 references indexed in Scilit:
- Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancerProteomics – Clinical Applications, 2009
- The multiplex bead array approach to identifying serum biomarkers associated with breast cancerBreast Cancer Research, 2009
- Human body fluid proteome analysisProteomics, 2006
- Evaluation of Multiprotein Immunoaffinity Subtraction for Plasma Proteomics and Candidate Biomarker Discovery Using Mass SpectrometryMolecular & Cellular Proteomics, 2006
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Cancer biomarkers: a systems approachNature Biotechnology, 2006
- Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion columnProteomics, 2006
- Effect of Immunoaffinity Depletion of Human Serum during Proteomic InvestigationsJournal of Proteome Research, 2005
- ICAT-MS-MS time course analysis of atrophying mouse skeletal muscle cytosolic subproteomeMolecular BioSystems, 2005
- Perspective: A Program to Improve Protein Biomarker Discovery for CancerJournal of Proteome Research, 2005